Tirzepatide

Dual Incretin Signaling • Metabolic Regulation • Appetite Awareness

Tirzepatide is a prescription-only injectable therapy that engages both glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptor pathways involved in appetite signaling, nutrient sensing, and metabolic regulation. Through this dual-pathway activity, tirzepatide supports coordinated gut-brain signaling associated with satiety awareness and metabolic balance.

Within clinician-directed wellness and optimization frameworks, tirzepatide is utilized as part of structured programs focused on metabolic resilience and sustainable physiological regulation. Its dual incretin mechanism allows for a broader signaling profile when integrated into a comprehensive care plan that includes nutrition strategy, lifestyle support, and recovery optimization.

Tirzepatide therapy is not appropriate for all individuals and is only considered following medical evaluation. Dosing, duration, and protocol structure are determined on an individualized basis according to clinical need, goals, and tolerance.

ASPN Insight

At ASPN, tirzepatide is positioned as an advanced metabolic signaling therapy, implemented selectively when dual-pathway incretin support is clinically appropriate and always within a long-term strategy focused on insulin sensitivity, metabolic signaling integrity, and sustainable outcomes.

Who This May Be Considered For

Tirzepatide may be evaluated by an ASPN clinician for individuals seeking:

• Support for coordinated appetite signaling awareness

• Enhanced metabolic regulation consistency

• Clinician-supervised metabolic optimization

Final determination is made by a licensed medical provider following individualized assessment.

Prescription & Payment Notice

Tirzepatide is a prescription-only injectable therapy provided exclusively within ASPN’s clinician-guided programs.

Tirzepatide is prescribed by a licensed medical provider and dispensed through a U.S.-licensed compounding pharmacy in accordance with applicable state and federal regulations. ASPN does not manufacture, compound, or dispense prescription medications.

To ensure appropriate medical evaluation, protocol alignment, and individualized clinical oversight, orders for prescription products are subject to a temporary payment authorization hold at checkout. Charges are finalized only after prescription approval and dispensing are completed.

This process supports safety, regulatory compliance, and personalized care as part of ASPN’s concierge medical model.

Prescription-only product. Intended to support normal metabolic and physiological function under the supervision of a qualified healthcare professional. Not intended to diagnose, treat, cure, or prevent any disease.